ArticleHaematologica2024

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.

Steven Le Gouill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.